Genitourinary Cancers

>

Latest News

The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.
Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer

August 29th 2024

The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.

Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.
Frontline Nivolumab Combo Improves TFS Vs Sunitinib in Advanced RCC

June 9th 2024

Additionally, PFS data in the CLEAR trial confirm the benefit of the lenvatinib combination in patients with clear cell RCC regardless of PD-L1 IHC.
Lenvatinib Combo Improves Clinical Benefit in Clear Cell RCC Subgroups

June 4th 2024

Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.
HK2-Targeting Radioligand Shows Responses With Some AEs in Metastatic CRPC

June 4th 2024

Pembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.
Pembrolizumab Combo Yields Efficacy in Penile Squamous Cell Carcinoma

June 4th 2024

Latest CME Events & Activities

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
4748495051